Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 USD | +0.62% | +4.38% | +59.41% |
05-10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
05-08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.41% | 293M | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children